secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0001140361-23-057889
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics appoints Dr. Han Ying as CEO effective Jan 15, 2024; Dr. Charles Wu retires for health reasons
--------------------------------------------------------------------------------

- CEO Dr. Charles Wu resigns as CEO and board member effective Jan 15, 2024 due to retirement for health reasons; no disagreements.
- Dr. Han Ying appointed CEO effective Jan 15, 2024; currently a director; base salary $350,000.
- Dr. Ying has over 20 years experience in immunology, biotech startups, and cancer immunotherapy; previously COO of Base Therapeutics.
- CEO severance provides 12 months base salary upon involuntary termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/ef20016739_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-057889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer